Cell Therapy News

Second-line therapy with axicabtagene ciloleucel induced a complete metabolic response in 71% of adults with relapsed or refractory large B-cell lymphoma ineligible for autologous stem cell transplant, results of a phase 2 study showed.

An infusion of lisocabtagene maraleucel induced deep and durable responses among most adults with relapsed or refractory follicular lymphoma, according to results of the phase 2 TRANSCEND FL trial.

Patients with multiple myeloma who exhibited sustained minimal residual disease negativity after treatment with ciltacabtagene autoleucel achieved longer PFS and duration of response, according to study results.

The FDA announced several regulatory actions the past few weeks.

Now that chimeric antigen receptor T-cell therapy has become part of the treatment landscape in hematologic malignancies, researchers are focused on developing more potent, less toxic agents that can be used in earlier treatment settings.

An investigational chimeric antigen receptor T-cell therapy induced responses among patients with indolent lymphomas, according to topline data released by the agent’s manufacturer.

Nirali N. Shah, MD, MHSc, was a self-proclaimed “big math nerd” growing up.

The FDA lifted a partial clinical hold it placed on a program designed to investigate a chimeric antigen receptor T-cell therapy for treatment of relapsed or refractory multiple myeloma.

The FDA placed a formal clinical hold on a phase 1 trial that has been paused since the death of a study participant more than 2 months ago.

An international research collaboration has contributed new insights into how the gut microbiome contributes to the effectiveness of immunotherapy for cancer.